Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
20.02
Price to sales ratio
2.62

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
146
SNY
Sanofi - American Depositary Shares
43.32 USD+0.32%+1.40%-0.94%-10.51%105.65 B USD
418
ONC
BeOne Medicines Ltd - American Depositary Shares
311.89 USD+1.74%+2.85%+16.25%-1.21%34.67 B USD
1187
CGON
CG Oncology, Inc. - Common stock
72.18 USD+0.57%+4.96%+19.42%+65.70%6.37 B USD
1302
ORKA
Oruka Therapeutics, Inc. - Common Stock
85.93 USD-1.76%-0.99%+24.45%+167.95%5.18 B USD

Frequently asked questions about Biogen Inc. - Common Stock

What is the Biogen Inc. - Common Stock stock price today?

The current price of Biogen Inc. - Common Stock (BIIB) is 190.97. Over the past 24 hours, the stock has changed by -0.51%. Follow the BIIB chart for real-time price dynamics.

What is the stock ticker of Biogen Inc. - Common Stock?

Biogen Inc. - Common Stock trades under the ticker BIIB. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Biogen Inc. - Common Stock stock going up?

BIIB has changed by -6.17% over the last week, -4.37% over the last month, and +48.63% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Biogen Inc. - Common Stock net income for the last quarter?

Biogen Inc. - Common Stock reported net income of 319.5 M for the last quarter. The previous quarter showed -48.9 M, which means net income changed by +753.37%.

How many employees does Biogen Inc. - Common Stock have?

As of the latest available data, Biogen Inc. - Common Stock has 7 500 employees. Workforce size can provide additional context about the company's scale and operations.

What is Biogen Inc. - Common Stock EBITDA?

Biogen Inc. - Common Stock EBITDA is 582.1 M, and its EBITDA margin is 23.49%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Biogen Inc. - Common Stock stock?

You can buy Biogen Inc. - Common Stock (BIIB) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Biogen Inc. - Common Stock stock?

Investing in Biogen Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the BIIB chart and related analysis on metatrader.com as part of your research.

Biogen Inc. - Common Stock

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

News